Monday, 20 Nov 2017

You are here

The RheumNow Week in Review – 14 July 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

  1. FDA has announced Arthritis Advisory Hearing on Aug 2nd (Sirukumab in RA) and Aug 3rd (Tofacitinib in PsA) http://buff.ly/2uiBRM7
  2. Metanalyses suggest a decreasing risk of CVD in rheumatoid arthritis after 2000 http://buff.ly/2vgC3Zu
  3. Monitoring IgG4 related disease w/ ESR CRP IgG4 levels not reliable. but imaging w/ 18F-FDG PET/CT reflects activity http://buff.ly/2tiFk9132
  4. SLE nephritis & 64 controls show pregnancy on lupus nephritis does not increase SLE flares, renal outcomes or CKD https://t.co/gK1lzJTZc9
  5. NEJM Study >73K shows Improved diet quality over 12 yrs associated w/ decreased risk of death (7-17% less mortality) https://t.co/2MOTfTiFPs
  6. Baricitinib gets market approval in Japan (https://t.co/9c0JmNMWjq) & NICE recommends Oluminant for UK approval (https://t.co/2Zchi0Kev3)
  7. IOM review shows uninsured have poorer health & shortened lives;Concludes health insurance reduces the risk of death https://t.co/0ndNNGzIoV
  8. Warnings section of the OTEZLA (apremilast) label updated to include risk of severe diarrhea, nausea, and vomiting. https://t.co/ljdKlcUlPbRT
  9. Population study of 40K Dutch finds ACPA positivity in 1%; assoc w/ age, smoking, female & RA;but only 15-20% had RA https://t.co/96DvKWPYTL
  10. increased pregnancy-induced type I IFN-inducible gene expression observed in preg RA women who improved during preg https://t.co/VwFrpH18YGRT
  11. Orencia Approved for Use in Psoriatic Arthritis  
  12. Alendronate Use in Steroid Treated Patients Lowers the Risk of Hip Fracture
  13. Withdrawal of TNF Inibitors Fails in Most RA Patients
  14. Statins Improve Survival in Ankylosing Spondylitis

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

Jack-I may have mentioned this in the past but again wonder if the improvement of CVD in RA patients may be a result of the markedly decreased use of NSAIDs as background therapy in RA patients on cDMARDs and bDMARDs since 2000.-D,Knapp
I think yours is a very valid point as research has shown a definite decline in NSAID use after the VIOXX/Cox-2 FDA hearing. But are rheums using more low dose prednisone instead? Researchers should control for these issues in their analyses. Good Point! JC

More Like This

The RheumNow Week in Review - 17 November 2017

Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com. This week he covers FDA warnings on gout drugs, steroid use in Australia, biosimilars lost savings and methotrexate hepatotoxicity in psoriatic arthritis (PsA).

Podcast of ACR17 - Day 4

Care to learn what you missed at last weeks ACR 2017 meeting in San Diego?  Here are 4 one hour audio podcasts - each with a compliation of 2-4 minute reports from Drs. Cush, Kavanaugh, the RheumNow Faculty and other rheumatology thought leaders and researchers.  Another good way to learn from RheumNow.

The ACR17 RheumNow Week in Review - 10 November 2017

This special edition of the RheumNow Week in Review covers highlights of selected sessions from the 2017 ACR annual meeting in San Diego. Dr. Jack Cush reviews lupus and the microbiome, daily podcasts, pregnancy and lactation, osteoporosis drug holidays and screening for pulmonary hypertension.

Many thanks to the RheumNow Faculty for their work and expertise!

Podcast of ACR 17 - Day 3

Check out this compilation of our ACR17 Day 3 broadcasts, merged into a single one hour podcast !

ACR 2017 - Day 3 and 4 Highlights

Day 3 at the annual meeting was rich with information. Yet the most anticipated and best attended session was the Late Breaking Abstracts and the session revealing the new ACR/NPF Guidelines for Psoriatic Arthritis (more on the latter in another report).  Day 4 was full of review sessions and a modicum of original content and for me, the 7:30AM Rheumatology Roundup.